SEC Form 4 · accession 0001209191-19-008551
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Officer — President and CEO · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $14.00 | Feb 6, 2019 | A | 505,000 | A | — | Feb 5, 2029 | Common Stock | 505,000 | 505,000 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 6, 2019 | A | 15,000 | A | — | — | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F3Subject to the Reporting Person providing continuous service to the Issuer, 25% of the shares subject to the RSU shall vest on each annual anniversary of January 1, 2019.